The markets advanced further into record territory during the midday with the Dow rising 10 points to 15,066 on upbeat earnings. Nasdaq gained 12 points to 3409.
On the upside
A Seeking Alpha contributor expects Affymax (Nasdaq: AFFY) to return OMONTYS to the market this year after successfully addressing adverse patient reactions.
Whole Foods Market (Nasdaq: WFMA) reported higher second quarter earnings and revenue prompting the company to lift its full year earnings guidance.
J.C. Penney (NYSE: JCP) reported that it spent less cash than expected in the first quarter.
On the downside
Axiall (NYSE: AXLL) disappointed by falling to an unexpected loss for the first quarter.
Oclaro (Nasdaq: OCLR) blamed continued softness in the telecommunications market for widening third quarter losses.
Concerns that the Food and Drug Administration may approve a generic version of Jazz Pharmaceuticals' (Nasdaq: JAZZ) narcolepsy medication Xyrem sank shares of the specialty biopharmaceutical.
In the broad market, advancing issues outpaced decliners by a margin of more than 5 to 3 on the NYSE and by nearly 5 to 4 on Nasdaq. The broader S&P 500 index rose 3 points to 1629.